Innovate UK

Z-PULSE, a spin-off from the University of Surrey, creates wearable health sensors that run on their own power.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Esox Biologics provides innovative and sustainable solutions for aquatic veterinary medicine. The company offers a disease prediction platform called eForesee, which uses data-driven predictions unique to individual farms. Regular monitoring of the aquatic environment and livestock health is a key component of their services. Esox Biologics utilizes extensive knowledge of the aquatic microbiome to prevent the spread of infectious diseases among aquatic animals by collecting environmental DNA and employing next-generation sequencing technologies.

Axial3D specializes in 3D printing for healthcare, focusing on creating precise, patient-specific physical models derived from CT and MRI scans. Their online ordering portal enables secure uploads, with an expert team using advanced technology to deliver these models directly to consultants. The company aims to enhance surgical planning, technique development, and ultimately improve patient outcomes by integrating 3D printing into mainstream medical practice.

Chromatwist develops innovative fluorescent dyes that become visible under UV light. Their patented technology platform enables the creation of fluorophores used in bio-sensing (like flow cytometry) and bio-imaging (such as multiphoton microscopy) within the healthcare sector.

LaennecAI is a clinical AI company specializing in chronic disease management solutions. It has developed a medical device, a digital stethoscope, which transforms modern smartphones into powerful diagnostic tools. The company's technology enables precise monitoring and analysis of respiratory and cardiac sounds, facilitating telemedicine, remote patient monitoring, and virtual wards. This ensures patients receive in-depth, reliable analysis and continuous care.

Reneural develops innovative, accessible technologies focused on improving cardiovascular disease treatment and management. Their flagship product is a wearable smart medical system designed to prevent blood clots in lower limbs, usable both clinically and at home.

Myogenes provides psychiatric tests, heredity cancer tests, and mental health mind maps.

Biovit is a company that specializes in the development of fortified foods. It uses 100% organic plant extracts, naturally rich in vitamins and minerals, to enhance the nutritional value of its products. The company aims to address health and environmental issues such as obesity and malnutrition, while also reducing food waste. Biovit has clinically developed and tested organic micronutrient blends for use in various food and beverage products, as well as supplements, providing consumers with organically sourced, nutrient-dense options.

Naitive is a population health company that develops AI-enabled clinical pathways. It uses artificial intelligence, clinical data, digital interventions, and scalable computational capabilities to enhance chronic disease case-finding, treatment, and care coordination, aiming to transform patient care and reduce associated costs.

Awen Oncology is a pre-clinical stage pharmaceutical company focused on developing novel cancer therapies. It specializes in targeting 'developmentally-silent oncogenic drivers', which are genes that contribute to cancer growth but are not typically targeted by existing treatments. The company's approach combines expertise in cell and molecular biology with advanced structural biology and in-silico drug screening to rapidly and efficiently identify and develop effective cancer treatments.

Fuse Diagnostics is a company dedicated to providing lab-quality diagnostic information through innovative and cost-effective testing solutions. The company manufactures diagnostic products designed to deliver accurate results for various applications, including food and water testing, bioprocessing industry needs, and cell biology research. Fuse Diagnostics aims to make high-quality diagnostic information accessible wherever it is needed, offering low-cost test kits with integrated readout technology that provide rapid results.

Presymptom Health is a medical technology company dedicated to advancing healthcare through the development of pre-symptomatic diagnostic tests and clinical decision support algorithms. The company focuses on creating innovative blood tests designed to detect illnesses at an early stage, particularly aiming to predict the onset of sepsis up to three days before symptoms manifest. By enabling earlier intervention, Presymptom Health seeks to improve critical care outcomes and enhance patient management, ultimately contributing to better survival rates and healthcare efficiency.

Cortirio is a developer of portable brain imaging technology aimed at improving the diagnosis and treatment of traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company designs portable scanners that utilize near-infrared imaging to deliver high-resolution, point-of-care medical imaging. These wearable devices provide critical information throughout the clinical pathway, facilitating automatic analysis and efficient data transfer. By equipping clinicians with rapid and accurate diagnostic tools, Cortirio enhances decision-making processes and improves care for patients suffering from brain injuries and strokes, ultimately aiming to reduce treatment times and prevent long-term disability or death.

Founded in 2019, Occuity specializes in the research, design, and manufacture of non-contacting optical instruments for use in healthcare diagnostics and monitoring. The company develops a range of handheld meters that work by shining light into the eye and analyzing the return signal, enabling direct measurements for optometrists, ophthalmologists, and other healthcare professionals to monitor various conditions including diabetes and Alzheimer's disease.

AMPLY Discovery uses machine learning and synthetic biology to mine large biological datasets and identify novel drug and nutraceutical candidates. The company combines an in silico and in vitro platform to discover first-in-class molecules and to tackle cancer, metabolic diseases, and multidrug-resistant infections. It develops a drug discovery studio that leverages artificial intelligence to digitize life’s natural diversity and to identify putative drug candidates based on function, enabling researchers to pursue new therapeutic molecules for hard-to-treat diseases.

PulmoBioMed is a company focused on providing innovative solutions for clinicians and researchers through non-invasive sampling of fluids. The firm has developed a passive fluid aerosol sampler designed to capture exhaled breath condensate and aerosol samples. This product effectively segregates exhaled and environmental particles by size, addressing critical challenges such as sample contamination and loss. PulmoBioMed's technology aims to generate highly reproducible data with precise digital molecular analysis, facilitating the study of biological agents and supporting metabolomic profiling. Through its advancements, the company seeks to enhance research capabilities and improve patient outcomes in the field of respiratory health.

Lucida Medical develops artificial intelligence–based healthcare technology to aid clinicians in the detection and diagnosis of cancer. Its platform analyzes imaging data from MRI and integrates imaging and multi-omics biomarkers and reporting tools to support cancer screening and diagnosis, with the aim of making detection more accurate, accessible, and faster while reducing costs. The company’s first product, Pi, is designed to assist in diagnosing prostate cancer using multiparametric or diffusion MRI and is a CE marked medical device.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Holly Health is a digital platform that translates health intentions into daily actions to support mental and physical wellbeing. The service delivers personalized habit coaching, chronic-condition support, and mental health resources through an AI-powered system designed to emulate a human health coach. It has been recognized by ORCHA as a top health app for weight management, stress reduction, wellness, and sleep. Since its international launch in summer 2021, Holly Health has pursued broad adoption and partnerships with primary care practices in the UK, numbering over 100 to date, with a mission to reach millions of users. The platform operates directly with individuals and through integration into primary care settings to help users sustain healthier behaviours and improve overall wellbeing.

Holly Health is a digital platform that translates health intentions into daily actions to support mental and physical wellbeing. The service delivers personalized habit coaching, chronic-condition support, and mental health resources through an AI-powered system designed to emulate a human health coach. It has been recognized by ORCHA as a top health app for weight management, stress reduction, wellness, and sleep. Since its international launch in summer 2021, Holly Health has pursued broad adoption and partnerships with primary care practices in the UK, numbering over 100 to date, with a mission to reach millions of users. The platform operates directly with individuals and through integration into primary care settings to help users sustain healthier behaviours and improve overall wellbeing.

At Holly Health, we are transforming the way individuals approach mental and physical well-being. Founded in 2020, we’ve developed an AI-powered digital health coach that empowers users to turn their health intentions into clear, actionable steps. Our personalized, compassionate service is designed to fit seamlessly into everyday life, supporting long-term, sustainable health changes. Using proprietary AI systems, Holly Health mimics the guidance of a human health coach, offering support in areas such as weight management, stress reduction, wellness, and sleep. We are proud to be ranked among the top 3 health apps by ORCHA, the world’s leading health app evaluation body, with a score of 89%. Since our international launch in 2021, Holly Health has been on a mission to improve the lives of 5 million people by 2025. We are rolling out partnerships with over 100 primary care practices in the UK, helping healthcare professionals support patients with preventative health measures and ongoing well-being. At Holly Health, we believe that health is not a destination but a journey. By offering tailored, science-backed coaching, we make it easier for people to prioritize their well-being every day. Join us as we revolutionize digital health coaching for the modern world.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

ZiO Health is a biotechnology company that develops pocket-sized devices featuring proprietary biosensor technology and machine learning algorithms. These devices enable real-time laboratory testing at the point-of-care, enhancing patient care by combining immediate results with individual patient profiles.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

Peptimatrix is a biotechnology company specializing in the development of an innovative, animal-free 3D cell culture platform. Utilizing a peptide hydrogel technology, the company aims to reduce and replace the use of animals and animal-derived products in drug development and research. By combining expertise from matrix biologists, cancer scientists, toxicologists, and biomaterial engineers, Peptimatrix offers a more reproducible, reliable, and ethical alternative to traditional cell culture methods. The company's mission is to provide researchers with a better way to model development and disease.

Kalium Health Ltd is a medical technology company based in Cambridge, United Kingdom, that specializes in designing and manufacturing innovative tests for blood potassium concentration. Founded in 2018 and previously known as Kalium Diagnostics Ltd, the company focuses on patient-centric approaches to manage kidney disease, which significantly impacts healthcare costs. Kalium Health is developing a user-friendly finger-prick blood test that allows patients to monitor their potassium levels conveniently and affordably, addressing a critical risk associated with kidney disease. This technology aims to provide real-time, clinically actionable health insights into cardiorenal diseases, thereby transforming the standard of care for millions of patients. With a clear regulatory pathway and a targeted go-to-market strategy, Kalium Health is positioned to make a significant impact in the field of kidney care.

genedrive plc is a commercial stage medical devices company, targeting opportunities in infectious diseases, biosurveillance, and animal applications. Our Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based molecular diagnostic tests via a 'razor/razor blade'​ business model across an increasing range of applications. Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid diagnosis and decision making.

SMi Systems is a biomedical research company that develops single-molecule discovery and diagnostic tools. Its automated, high-throughput platform uses super-resolution microscopy coupled with deep learning for multi-omic detection, enabling drug developers to observe molecular interactions across various diseases.

SMi Systems is a biomedical research company that develops single-molecule discovery and diagnostic tools. Its automated, high-throughput platform uses super-resolution microscopy coupled with deep learning for multi-omic detection, enabling drug developers to observe molecular interactions across various diseases.

CGT Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. Based in central London with over 120 experts and state-of-the-art laboratories, CGT Catapult offers a comprehensive platform for product development, clinical trials, manufacturing, regulatory support, health economics, and market access expertise. Additionally, they are constructing a £55 million large-scale GMP manufacturing centre to accelerate the delivery of cell and gene therapies to patients worldwide.

Kids Speech Labs is a digital health company developing AI-driven solutions to manage and improve speech and language therapy services.

GG Care helps care residents stay independent and help carers monitor their well-being, comfort, and mood. They serve people with dementia maintain daily routines and stay socially connections shown to reduce cognitive decline and increase happiness and creates an environment to help reduce agitation - significantly reducing the cost of care.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

Tycho Medlink is to help people achieve new levels of rehabilitation through digital therapy.

Founded by specialists in nanotechnology, medicinal chemistry, and artificial intelligence, Nanovery aims to enable early detection of cancer through a rapid and affordable blood test. Its core technology involves AI-powered nanorobots that capture circulating tumor DNA and emit a fluorescent signal for point-of-care detection.

GenoMe Diagnostics is a biotechnology company focused on developing innovative blood tests for early cancer detection. Its flagship product, OvaME, aims to improve the current standard of CA125 blood tests.

Syndi is a digital health support recommendation platform that utilizes machine learning and digital phenotyping, with a primary focus on mental health. The company develops technology-driven solutions aimed at enhancing individuals' health by providing effective and accessible support. Syndi's platform employs passive smartphone data collection to gather moment-to-moment information about users, allowing it to deliver personalized and immediate care. This innovative approach not only facilitates connections between patients and healthcare providers but also measures the effectiveness of applications and digital services in treating invisible disabilities. Through its commitment to leveraging technology and research, Syndi seeks to improve healthcare outcomes for its users.

Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.

Healthera Ltd., established in 2015 and headquartered in Cambridge, UK, specializes in developing digital health solutions. Its flagship product, Healthera, is a pharmacy-integrated medication management app that offers automatic prescription reminders, smart labelling, scheduling, health condition tracking, and professional advice from pharmacists. Additionally, Healthera operates a healthcare marketplace that connects patients with local pharmacies and GPs, enabling faster medicine delivery and personalized care. The company partners with over 1000 pharmacies and Clinical Commissioning Groups (CCGs) across the UK, reaching over 20 million people. Healthera's technology is accredited by NHS Digital and aims to improve prescribing efficiency, patient experience, and reduce wastage within the NHS.

NIQS Technology is a spin-out from the University of Leeds specializing in innovative quantum glucose management solutions aimed at transforming diabetes care. The company has developed a patented, non-invasive glucose monitoring technology that employs a contact-based wearable device made of nano-engineered glass. This device mimics the optical properties of glucose, allowing for continuous, accurate glucose level monitoring without the need for needles or blood sampling. By providing accessible and user-friendly monitoring solutions, NIQS Technology seeks to empower individuals living with diabetes to manage their condition more effectively and improve their overall quality of life, while minimizing the risk of complications associated with traditional glucose management methods.

Emm is a company focused on consumer health technology, developing tools to help individuals manage their health on their terms. It is building a menstrual cup with integrated biosensors designed to track biometric data and deliver personalized insights about menstrual health. The device aims to redefine period experiences by providing actionable information that helps users understand their health through technology and expert knowledge.

52 North Health is a medical technology company focused on enhancing healthcare outcomes for cancer patients. It specializes in an AI-driven, portable finger prick blood test that measures neutrophil count and C-reactive protein (CRP) levels at home. This enables early detection of neutropenic sepsis risk during chemotherapy, improving patient safety and quality of life. The device facilitates timely management of the condition, offering a reliable and cost-effective solution for both patients and healthcare providers.

Vann is a platform for people affected by cancer aiming to help millions of people globally and revolutionize cancer research and care. Vann has been backed by the Oxford University Innovation, Innovate UK, OxLEP European Regional Development Fund, and UK angel investors and is based in the UK.

iEthico is a technology company that specializes in streamlining the sourcing of medicines through its innovative digital platform. The company's automated cloud-based service tracks essential data and provides critical intelligence, alerting users to shortages and connecting them with reliable sources. iEthico's platform is approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and features an automated regulatory process that eliminates paperwork, saving pharmacies significant time and effort. Following successful market testing, iEthico's solution is being rolled out to community pharmacies and NHS Trusts across the UK. The company aims to empower pharmacists by delivering insights that help mitigate the impact of medicine shortages, enabling distributors and providers to navigate multiple suppliers efficiently, reduce costs, and supply medicines across various geographies.

Silveray develops affordable large-area direct conversion detectors for the X-ray imaging market.

Drill Surgeries is a company dedicated to enhancing the outcomes of trauma and orthopedic surgeries through its innovative AI-powered navigation system. This technology aims to significantly reduce the failure rate of surgeries from 36% to less than 4% by providing real-time guidance during osteosynthesis procedures. By employing proprietary AI algorithms and mixed reality technologies, Drill Surgeries facilitates a remarkable 83% reduction in operating room time. Additionally, the company’s solutions eliminate the need for unnecessary X-rays, leading to substantial cost savings of approximately $2,000 per operation for hospitals. Through these advancements, Drill Surgeries empowers doctors to perform complex procedures more efficiently and effectively, ultimately improving patient care and operational efficiency in healthcare settings.

Acurable is a London-based MedTech company that develops wearable sensor-based devices for at‑home diagnosis and management of respiratory conditions. Its flagship AcuPebble captures internal body sounds using non-invasive sensors and transmits data to a mobile device, where algorithms extract clinical parameters and biomarkers relevant to sleep apnea. The system enables remote assessments by patients and healthcare providers, supporting home monitoring without hospital visits and facilitating more accessible, cost-effective care. Founded in 2016, Acurable emphasizes research-driven development to advance at‑home respiratory care.

ProtonDx is a diagnostic platform that specializes in molecular testing services, focusing on the rapid and precise detection of multiple pathogens from samples. The company develops point-of-care diagnostic test devices aimed at assisting healthcare professionals in diagnosing infectious diseases. Utilizing innovative microchip technology, ProtonDx integrates molecular biology with machine learning, allowing for swift deployment in clinical settings. This enables healthcare organizations to efficiently manage infected patients and monitor pandemic situations in real-time. ProtonDx emphasizes speed, sensitivity, specificity, and convenience in its offerings, positioning itself as a vital resource for frontline healthcare staff.

AMPLY Discovery uses machine learning and synthetic biology to mine large biological datasets and identify novel drug and nutraceutical candidates. The company combines an in silico and in vitro platform to discover first-in-class molecules and to tackle cancer, metabolic diseases, and multidrug-resistant infections. It develops a drug discovery studio that leverages artificial intelligence to digitize life’s natural diversity and to identify putative drug candidates based on function, enabling researchers to pursue new therapeutic molecules for hard-to-treat diseases.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Medwise.ai operates a customizable search platform that uses natural language processing and artificial intelligence technologies to provide clinical decision support for doctors. Its real-world data offers insights to various healthcare stakeholders, enabling doctors to organize medical knowledge and enhance patient care outcomes.

GenoMe Diagnostics is a biotechnology company focused on developing innovative blood tests for early cancer detection. Its flagship product, OvaME, aims to improve the current standard of CA125 blood tests.

AgPlus Diagnostics Ltd. is a UK-based company specializing in the development of diagnostic platform technology aimed at providing quantitative point-of-care (PoC) testing solutions for various clinical applications, including both human and veterinary diagnostics. Founded in 2009 and headquartered in Sharnbrook, the company designs, manufactures, and supplies diagnostic tests and associated readers. AgPlus Diagnostics focuses on creating portable diagnostic devices that utilize electrochemical signaling and measurement systems, enabling healthcare providers to deliver personalized care through rapid and accurate testing. This innovative approach facilitates timely diagnostic results, allowing healthcare professionals to make critical treatment decisions quickly, ultimately benefiting patient outcomes.

Chromatwist develops innovative fluorescent dyes that become visible under UV light. Their patented technology platform enables the creation of fluorophores used in bio-sensing (like flow cytometry) and bio-imaging (such as multiphoton microscopy) within the healthcare sector.

CN Bio Innovations Ltd, established in 2008 and headquartered in Cambridge, UK, specializes in developing and providing Organ-on-Chip devices to pharmaceutical and biotech companies. These devices enable more accurate preclinical drug testing by replicating the physiological functions of human organs. CN Bio's offerings include microphysiological systems and consumables, used by various industries to analyze novel compounds, assess toxicity and safety, and support research scientists in investigating biological processes. The company's flagship product, the LiverChip platform, features a full viral lifecycle model of hepatitis B, currently employed in drug discovery collaborations with leading pharma and biotech firms. CN Bio, part of Hong Kong-based CN Innovations Holdings Limited, works closely with academic experts and is backed by prestigious grants, aiming to accelerate the development of transformative therapies worldwide.

Invatech Health provides software as a service solution. It also develops several products to address unresolved issues in areas such as domiciliary care and mental health. It specializes in the healthcare and social care industries.

4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.

Decorte Future Industries is a venture-backed startup focused on developing artificial intelligence technology to extract health data from sound. The company employs advanced machine-learning methods to analyze audio recordings captured by standard microphones, allowing for the extraction of complex biometrics including cardiovascular and respiratory health indicators, among other human health markers. This innovative approach enables clients to gather intricate health data efficiently and at scale, transforming how health information is collected and utilized.

BioFab is developing innovative new products for healthcare diagnostics with a particular focus on point-of-care testing (POCT) applications. Our vision is to create a truly universal diagnostic platform that can bring the clinical lab to the patient. Our innovative approach will enable this vision by offering a diverse range of test cartridges which can run on a single, universal reader device. It will not need any user training and will simply require the addition of the patient sample. Fully automated processing will then take place in a totally enclosed cartridge and will then deliver laboratory grade results without risk of cross-contamination. We are developing a test for Covid-19 with the support of an Innovate UK Smart award and will expand the product range to cover cardio-vascular disease, respiratory/gastric infections, blood infections (sepsis), STDs, Cancer and other conditions. We also have the ability to access the rapidly expanding Chinese market and have route-to-market and manufacturing base via established partners in China.

AgPlus Diagnostics Ltd. is a UK-based company specializing in the development of diagnostic platform technology aimed at providing quantitative point-of-care (PoC) testing solutions for various clinical applications, including both human and veterinary diagnostics. Founded in 2009 and headquartered in Sharnbrook, the company designs, manufactures, and supplies diagnostic tests and associated readers. AgPlus Diagnostics focuses on creating portable diagnostic devices that utilize electrochemical signaling and measurement systems, enabling healthcare providers to deliver personalized care through rapid and accurate testing. This innovative approach facilitates timely diagnostic results, allowing healthcare professionals to make critical treatment decisions quickly, ultimately benefiting patient outcomes.

Medwise.ai operates a customizable search platform that uses natural language processing and artificial intelligence technologies to provide clinical decision support for doctors. Its real-world data offers insights to various healthcare stakeholders, enabling doctors to organize medical knowledge and enhance patient care outcomes.

ONKO is a provider of unified cancer care. ONKO combines digital technology with the support of healthcare professionals to provide patients with personalised expertise from cancer dietitians, physiotherapists, specialist nurses and psychologists.

Thomson Screening is a supplier of software for health needs assessments, immunisations, and health screening. They offer schoolscreener software for managing and automating health program requirements. They also provide workscreener platform to provide critical health information to employers across sectors, such as the private sector and the public sector.

Game Doctor develops data-driven gamification technology. They offer services that include big data, mobile applications, health promotion, health marketing, public health, engagement, and behavior change.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

Appt is making preventive healthcare effortless and accessible. Appt uses behavioural economics and data analytics to increase the uptake of preventive healthcare appointments - earning practices additional income and helping the delivery of nationally set prevention targets. Furthermore, through end-to-end automation of the call and recall process, Appt reduces cumbersome practice workload saving practice staff valuable time.

Circada provides lighting systems designed to improve human health and well-being by aligning indoor lighting with the natural daylight rhythm. Its retrofit-ready lighting controls connect to existing tunable white LED drivers and use a standard light switch as an interface, enabling plug-and-play installation without complex commissioning. The company can tailor configuration before installation to meet specific project requirements, delivering circadian lighting that supports healthier indoor environments.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions and processes, particularly in the areas of infections and oncology. Its flagship product, True Point-of-Care, utilizes advanced molecular methods, including polymerase chain reaction (PCR), to deliver rapid and accurate results. This capability allows clinics and medical professionals to detect infections swiftly and make informed treatment decisions in a decentralized healthcare setting, ultimately improving patient outcomes.

Gendius Ltd. is a company based in Macclesfield, United Kingdom, founded in 2011 by Chris Genders and Rory Cameron. It specializes in developing an app-based platform designed to assist individuals living with diabetes. The company's flagship product, Intellin, leverages a patient's clinical history to identify unique high-risk areas for potential complications related to diabetes. By doing so, Intellin aims to empower users with clinically validated tasks and measures tailored to their specific risks, helping them manage their condition more effectively and reduce the likelihood of complications.

BrainWaveBank, established in 2015, is a UK-based brain health research company. It specializes in developing data-centric solutions to track and understand cognitive health. The company's flagship product, also named BrainWaveBank, is a wearable EEG headset that measures brain activity while users engage in mobile games, enabling daily tracking of cognitive health at home. This data is securely stored and analyzed, creating neurocognitive profiles for individuals and populations, and aiding clinical professionals in advancing brain health research and treatments. The company has offices in Belfast, Northern Ireland, and Dublin, Ireland.

Echopoint Medical Ltd, established in 2018 and headquartered in London, specializes in developing medical devices that incorporate optical-fibre based sensors. The company leverages optical fibre sensing technologies to enhance precision and efficacy in invasive cardiology and other minimally invasive procedures, with a focus on transforming the diagnosis and treatment of cardiovascular diseases.

Healum develops AI-powered collaborative software that empowers individuals with long-term conditions to monitor and understand their physical and mental health. The platform uses data-driven insights and evidence-backed interventions to support patients and facilitate personalized care.

Feebris Ltd is a UK-based company, founded in 2017 and headquartered in Saffron Walden, that specializes in developing artificial intelligence and machine learning algorithms for the detection of respiratory conditions. The company creates a mobile software platform that integrates with various point-of-care devices, such as digital stethoscopes and wearables. This technology is designed for community-based diagnosis and monitoring, allowing non-clinical users to identify early signs of deterioration in patients, thereby preventing complications and reducing the need for hospitalization. Feebris' team comprises experts in biomedical engineering, machine learning, global health, and business, all dedicated to transforming healthcare into a more equitable, personalized, and patient-driven system.

CGT Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. Based in central London with over 120 experts and state-of-the-art laboratories, CGT Catapult offers a comprehensive platform for product development, clinical trials, manufacturing, regulatory support, health economics, and market access expertise. Additionally, they are constructing a £55 million large-scale GMP manufacturing centre to accelerate the delivery of cell and gene therapies to patients worldwide.

Concentric Health is a company focused on transforming health decision-making through its innovative e-consent application. The application enhances efficiency by addressing backlog issues and minimizing medico-legal risks through the use of trusted content. It aims to simplify complex processes for both patients and clinicians, fostering shared decision-making that is informed by patient outcomes. By providing a secure and auditable platform, Concentric Health improves the overall experience for users, ultimately leading to better health outcomes.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Mendelian is a company focused on accelerating the diagnosis of rare genetic diseases. It employs advanced machine learning and knowledge reasoning techniques to analyze patients' clinical features, allowing physicians to identify the genes and mutations responsible for various undiagnosed conditions. By utilizing an intelligent agent, Mendelian streamlines the process of matching patients' phenotypic characteristics with potential genetic causes, thereby enhancing the ability of healthcare professionals to diagnose rare diseases more efficiently. This innovative approach aims to improve patient outcomes by enabling earlier detection and treatment of these complex conditions.

MediSieve Ltd. is a London-based medical device company specializing in Magnetic Blood Filtration (MBF) technology aimed at treating blood-borne diseases. Founded in 2014, the company has developed a system that utilizes a magnetic filter to physically remove infected blood cells from a patient's bloodstream. The process involves circulating blood through an external loop where targeted magnetic particles are infused, binding to disease-relevant targets. This filtered blood then passes through a magnetic filter that captures the particles and bound targets, allowing the unaffected blood to return to the patient without the particles entering their body. MediSieve's innovative approach is applicable to various conditions, including malaria, leukaemia, sepsis, and other blood-borne diseases, enhancing the efficacy and safety of existing therapies. The company operates out of the Imperial Incubator in White City, London, where it conducts product development and validation in its dedicated laboratory facilities.

BIOS Health is a pioneering company focused on developing neural digital therapies by harnessing data-driven insights from the human nervous system. Co-founded by researchers from Cambridge University, the firm aims to revolutionize precision medicine through the identification of neural biomarkers that link nerve activity to various medical conditions. BIOS's innovative approach holds promise for treating chronic diseases such as hypertension, diabetes, rheumatoid arthritis, and neurodegenerative disorders like Parkinson's and Alzheimer's. The company's expertise encompasses a diverse range of fields, including neuroscience, machine learning, software engineering, and biotechnology, allowing it to create advanced solutions for improving the quality of life for individuals suffering from these conditions. Additionally, BIOS is engaged in developing prosthetic connectors that standardize the interface between bionic devices and the body's nervous and soft-tissue systems, enabling enhanced control and feedback for patients with prosthetics.

Ieso Digital Health provides online, evidence-based mental health therapy via a digital platform, enabling one-to-one cognitive behavioral therapy delivered by accredited therapists in a virtual, convenient setting. The service covers common mental health conditions such as anxiety, depression, OCD, PTSD, sleep problems, and related issues, and also supports patients with chronic physical health problems, medically unexplained symptoms, and other cognitive concerns. The company uses proprietary technology, including natural language processing and artificial intelligence, to monitor therapist protocol adherence and risk in real time, enabling text-based therapy sessions. It serves health providers including the NHS, private individuals, and employers, expanding access to clinically validated care outside traditional in-person settings.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing innovative technology for assessing seizure susceptibility. The company has created a novel platform that focuses on diagnosing and prognosticating neurological conditions, specifically targeting epilepsy. Utilizing a patented seizure risk score derived from routine electroencephalogram (EEG) recordings, Neuronostics' technology aims to facilitate early diagnosis and prognosis of epilepsy. This advancement is designed to empower clinicians to enhance patient care and improve the quality of life for individuals living with this neurological condition.

Phico Therapeutics Limited is a biotechnology company based in Bourn, United Kingdom, that specializes in developing innovative antibiotics to combat antibacterial resistance. The company utilizes its proprietary SASPject platform, which employs small acid-soluble spore proteins delivered via targetable non-delivery vehicles to specific bacterial strains. Its product portfolio includes SASPject PT3, designed to target Pseudomonas aeruginosa; SASPject PT4 and PT5, which are aimed at Klebsiella pneumonia and Escherichia coli, respectively; and SASPject PT1.2, focused on Staphylococcus aureus. Additionally, Phico Therapeutics is working on an intravenous-engineered bacteriophage drug intended to treat ventilator-associated pneumonia by using engineered bacterial viruses in conjunction with antibacterial proteins to inhibit bacterial growth and toxin release. Founded in 2000, the company is dedicated to addressing critical challenges in antibiotic resistance through its advanced therapeutic approaches.

Mayden specializes in developing and managing cloud-based software solutions for the healthcare sector. They offer a range of services including patient management systems, operational management tools, online service assessment platforms, and secure hosting solutions. With offices near Bath and Chippenham, Mayden employs around 45 staff and associates, driven by a mission to enhance healthcare services through innovative technology.

Vitamica Ltd is a diagnostic technology company based in Bristol, United Kingdom, founded in 2018 as a spin-out from the University of Bristol. The company specializes in rapid antimicrobial susceptibility testing (AST) that enables the swift identification of pathogenic bacteria and their resistance to antibiotics. By utilizing advanced optical technology, Vitamica's innovative approach detects nanoscale fluctuations in live bacteria, providing clinicians with critical information to guide antibiotic treatment decisions. With a growing portfolio of intellectual property, Vitamica aims to make significant contributions to the healthcare, veterinary, and pharmaceutical sectors through its novel diagnostic methods.

PulmonIR is a medical technology company focused on developing innovative devices for the early detection and continuous monitoring of chronic obstructive pulmonary disease (COPD) and other lung diseases. Their products aim to improve diagnostic efficiency for healthcare professionals, ensuring timely and effective treatment for patients suffering from these conditions.

AccuRx is a healthcare communication platform that connects patients and medical professionals to streamline care. The platform enables SMS messaging, appointment reminders, referrals, patient surveys, and video consultations, and supports managing virtual wards, outpatient clinics, and follow-up pathways, helping to improve efficiency in primary care. Founded in 2016 and based in London, it is used by a large majority of GP practices and NHS trusts.

Eagle Genomics is a life sciences software company that provides data management and analytics platforms for genomics and related fields. Its solutions enable management, orchestration and exploitation of genomics and other life sciences data, turning diverse datasets into usable data assets and supporting end-to-end workflows from data integration and curation to analysis, visualization and sharing. The company combines biology, bioinformatics, data science, and enterprise software engineering to help pharmaceutical, consumer goods, and agricultural technology organizations shorten research cycles and improve decision making. Its offerings cover next-generation sequencing data management and analysis, cloud-based bioinformatics, biomarker discovery, microarray analysis, and pipeline design, as well as on-demand consulting and tools for managing research data. Headquartered in Cambridge, United Kingdom, with an international footprint, Eagle Genomics emphasizes building an enterprise information architecture for the genomics era, enabling customers to realize the value of digital assets and enhance productivity across R&D programs.

Andiamo is a custom medical wearables platform that focuses on providing innovative solutions for neuromuscular conditions, beginning with cerebral palsy. The company operates a digital clinic that connects families with specialists, ensuring they receive the necessary care and expertise when and where it is needed. By leveraging technology, Andiamo aims to improve the quality of life for individuals with neuromuscular disorders through tailored wearable devices and specialized medical services.

MyWay Digital Health is a global digital platform empowering individuals with long-term conditions, particularly diabetes, to self-manage their health. It offers personalized advice, educational resources, and access to health records via its user-friendly interface. Clinicians benefit from population analytics tools for improved decision support.

Miotify Ltd. is a company that specializes in developing software and online toolkits aimed at enhancing the quality of digital health applications. Founded in 2015 and based in Windsor, United Kingdom, Miotify's system is designed to empower both developers and non-IT personnel to create applications within a structured framework, ensuring quality is integrated from the outset. The software facilitates the auto-generation of evidence for regulatory submissions while transforming data from devices and sensors for remote patient monitoring in clinical trials. Additionally, Miotify's solutions provide medical practitioners and researchers with tools for iterations tracking, lifecycle management, and the analysis of clinical data. This enables healthcare professionals to make informed clinical decisions and gather insights that significantly improve patient care.

CN Bio Innovations Ltd, established in 2008 and headquartered in Cambridge, UK, specializes in developing and providing Organ-on-Chip devices to pharmaceutical and biotech companies. These devices enable more accurate preclinical drug testing by replicating the physiological functions of human organs. CN Bio's offerings include microphysiological systems and consumables, used by various industries to analyze novel compounds, assess toxicity and safety, and support research scientists in investigating biological processes. The company's flagship product, the LiverChip platform, features a full viral lifecycle model of hepatitis B, currently employed in drug discovery collaborations with leading pharma and biotech firms. CN Bio, part of Hong Kong-based CN Innovations Holdings Limited, works closely with academic experts and is backed by prestigious grants, aiming to accelerate the development of transformative therapies worldwide.

CHAIN Biotechnology Ltd. is a biotechnology company based in London, United Kingdom, that specializes in harnessing Clostridium bacteria for various applications. Founded in 2014, the company focuses on advancing fermentation processes through synthetic biology and automation, particularly utilizing Clostridium strains to produce chiral chemicals. These chemicals are incorporated into a range of products, including nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Notable developments include 3-hydroxybutyrate and (R)-methyl-3HB, a precursor used in glaucoma treatment. CHAIN Biotechnology also aims to create cost-effective fermentation routes from sugar. In addition to its work in fermentation, the company is exploring microbiome therapeutics, developing novel compounds aimed at treating chronic gut-related diseases using its proprietary drug development platform.

Activirosomes is a biotechnology company focused on the development of innovative vaccines and virotherapies designed to combat viral infections. Utilizing an active virosome technology, the company creates multivalent vaccines that target various health challenges, including cancer and infectious diseases such as avian and Zika viruses. Activirosomes is committed to producing effective, safe, and affordable solutions that address both existing and emerging viral threats, aiming to improve public health outcomes through its advanced therapeutic approaches.